Annals of Indian Academy of Neurology · 2011 · 34 citations · 10 references
MedicineNeurologyPharmacologyClinical PharmacologyNeurologic PharmacotherapyNeuropharmacologyAcute Ischemic StrokeCerebrovascular DiseaseNeuroprotectionNeuroprotective PharmacologyStrokeStroke PharmacotherapyAcute Ischemic Stroke TreatmentEdaravone TherapyFunctional Outcome EvaluationFunctional Outcome MeasurementMatched Control GroupNeuroprotective AgentsNeuroprotective MechanismsStroke Neuroprotection
BACKGROUND AND OBJECTIVE: Edaravone has potent antioxidant and free radical scavenger properties. Few Japanese studies had demonstrated its neuroprotective role in acute ischemic stroke (AIS). This study aims to evaluate the efficacy of edaravone in terms of functional outcome in a group of Indian patients of AIS. MATERIALS AND METHODS: Fifty patients of AIS were randomly divided into two groups. The study group received 30 mg of edaravone twice daily for 14 days by infusion, while control group received normal saline infusion as placebo. Outcome assessment was done by the Modified Rankin Scale (MRS). MRS score ≤2 at 90 days was considered as a favorable outcome. RESULTS: Of 25 patients, 18 (72%) had favorable outcomes (MRS ≤2) at 90 days in edaravone group, while 10 (40%) of 25 patients in placebo group had favorable outcome (P < 0.005). Two patients expired (one in each group) during treatment. The mean Barthel index increased from 41.20 ± 32.70 at baseline to 82.40 ± 18.32 at day 90 in edaravone group as compared with placebo group in which scores were 44.20 ± 22.76 at baseline and 68.20 ± 21.30 at day 90 (P < 0.005). CONCLUSIONS: We therefore conclude that edaravone effectively improves functional outcome in AIS.
10
Experience from a multicentre stroke register: a preliminary report.
PubMed · 1976 · 1.5K citations
Use of the Barthel Index and Modified Rankin Scale in Acute Stroke Trials
Geert Sulter, Christel Steen, Jacques De Keyser · Stroke · 1999 · 1.1K citations · Full text
Medicine, Neurology, Pharmacotherapy +17